

WuXi XDC and Celltrion sign MoU for integrated services for Antibody-Drug Conjugates

24 January 2024 | News

Aiming to accelerate the development of ADCs at a fast speed and with high quality

WuXi XDC, China-based contract research, development and manufacturing organisation (CRDMO) focused on antibody drug conjugate (ADC) and the other types of bioconjugate market, and South Korea-based Celltrion, Inc. have signed a Memorandum of Understanding (MoU) for comprehensive and integrated services which refer to the development, and manufacturing of bioconjugates include antibody-drug conjugates.

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP manufacturing, within the global territory.

WuXi XDC will be strategic service partner to support Celltrion's innovative pipeline advances, providing comprehensive services from process development to one-stop GMP manufacturing, aiming to accelerate the development of ADCs at a fast speed and with high quality.

Jong Moon Cho VP of Celltrion, commented, "WuXi XDC is an ideal partner for Celltrion given their advanced platform and broad expertise in ADC development and manufacturing."

Dr Jimmy Li, CEO of WuXi XDC, commented, "With our fully integrated, one-stop platform, we look forward to collaborating with Celltrion to expedite the development and manufacturing for ADC and other bioconjugate candidates."